GlassScriptPhysician profile
Melissa Armknecht
NPI 1689442063
$2,158.07
in general payments reported to CMS, 2019-2025
21 companies · $2,158 in 2025
The $2,158 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $504.50 | 2025 | |
| Gilead Sciences, INC. | $302.23 | 2025 | Livdelzi |
| Aimmune Therapeutics, INC. | $207.98 | 2025 | Zenpep, Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $205.15 | 2025 | Entyvio |
| Janssen Biotech, INC. | $193.90 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $152.85 | 2025 | Rezdiffra |
| Genzyme Corporation | $116.72 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $102.46 | 2025 | Dupixent |
| Ardelyx, INC. | $91.49 | 2025 | Ibsrela |
| Orphalan INC | $39.10 | 2025 | Cuvrior |
| Phathom Pharmaceuticals, INC. | $38.12 | 2025 | Voquezna |
| Pfizer INC. | $33.99 | 2025 | |
| Qol Medical, LLC | $30.66 | 2025 | Sucraid |
| Braintree Laboratories, INC. | $26.91 | 2025 | Suflave |
| Digestive Care, INC. | $17.88 | 2025 | Pertzye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $16.30 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.22 | 2025 | Iqirvo |
| Echosens North America, INC. | $16.00 | 2025 | Fibroscan |
| Novo Nordisk INC | $15.41 | 2025 | Wegovy |
| Csl Behring | $15.11 | 2025 | Kcentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.09 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Armknecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.